|
|
|
| Effect of Valsartan and Amlodipine on Serum ROCK1 and ROCK2 Levels in Patients with End-stage Renal Disease |
| CHENG Wei-ping, PEI Yuan-yuan |
| Department of Pharmacy,Yulin No.2 Hospital,Yulin Shaanxi 719000 |
|
|
|
|
Abstract 【Objective】 To study the clinical efficacy of valsartan and amlodipine in the treatment of end-stage renal disease (ESRD) and its effect on the level of serum Rho associated coiled coil protein kinase1 (ROCK1) and ROCK2. 【Methods】Ninety-two patients with ESRD in Yulin No.2 Hospital were randomly divided into the control group and the observation group,with forty-six cases in each group. Both groups were treated with hemodialysis,in which the control group was treated with amlodipine and the observation group was treated with valsartan and amlodipine. The curative effects of the two groups after 3 months of treatment were compared,and blood pressure level[systolic blood pressure (SBP),diastolic blood pressure (DBP)],the renal function[serum creatinine (SCR),urea nitrogen (BUN)],serum ROCK1 and ROCK2 levels,and quality of life[kidney disease and dialysis related quality of life (KDTA)] before and after 3 months of treatment were compared in both groups. The adverse reactions during treatment were counted as well. 【Results】The total effective rate in the observation group was 91.30%(42/46),which was higher than 76.09%(35/46) in the control group (P<0.05). After 3 months of treatment,DBP,SBP,SCr,BUN, and levels of serum ROCK1 and ROCK2 in the observation group were lower than those in the control group (P<0.05). The KDTA score in the observation group after 3 months of treatment was higher than that in the control group (P<0.05). The incidence of adverse reactions was 17.39%(8/46) in the observation group and 13.04%(6/46) in the control group. There was no significant difference between the groups (P>0.05). 【Conclusion】Valsartan and amlodipine are effective in the treatment of ESRD. They can lower blood pressure,improve renal function,reduce the levels of serum ROCK1 and ROCK2,improve the quality of life,have high safety,and can be popularized in clinic.
|
|
Received: 17 January 2022
|
|
|
|
|
|
[1] WELLES C C,CERVANTES L.Hemodialysis care for undocumented immigrants with end-stage renal disease in the United States[J].Curr Opin Nephrol Hypertens,2019,28(6):615-620.
[2] 苏慧萍,吕以培.终末期肾病顽固性高血压应用低钠HD联合血液透析滤过对血压节律的影响[J].解放军预防医学杂志,2019,37(5):43-44.
[3] 胡瑞玲.苯磺酸氨氯地平联合缬沙坦治疗慢性肾脏病1期合并高血压效果观察[J].白求恩医学杂志,2020,18(3):252-253.
[4] YU B,SLADJEVIC N,BLAIR J E,et al.Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening[J].Expert Opin Ther Targets,2020,24(1):47-62.
[5] 中国中西医结合学会肾脏疾病专业委员会.慢性肾衰竭中西医结合诊疗指南[J].中国中西医结合杂志,2015,35(9):1029-1033.
[6] 孙凌云,吴家祥,沈世忠,等.腹膜透析联合血液透析患者血浆肾素、血管紧张素Ⅱ水平变化情况[J].福建医药杂志,2020,42(2):41-43.
[7] EL-ETRIBY A M K,RAKHA S.Efficacy and safety of amlodipine/valsartan/hydrochlorothiazide single pill combination in Egyptian patients with hypertension uncontrolled on any dual therapy: an observational study[J].Curr Med Res Opin,2020,36(4):537-544.
[8] OH J K,SEO J S,PARK Y H,et al.Addition of amlodipine or valsartan for improvement of diastolic dysfunction associated with hypertension[J].J Cardiovasc Imaging,2020,28(3):174-182.
[9] 魏琳.苯磺酸氨氯地平结合缬沙坦用于长期透析伴高血压患者临床研究[J].中国社区医师,2019,35(10):69-71.
[10] 张子云,王素超,张祥玖,等.联合检测MAU、CysC、β2-MG评估缬沙坦/氨氯地平复方片对高血压早期肾损害的治疗效果[J].实验与检验医学,2020,38(5):969-970.
[11] 蔡剑凯,孙卓垒,黄曼丽.氨氯地平联合缬沙坦对老年原发性高血压合并糖尿病患者心肾功能及血清ROCK1水平的影响[J].中国医学创新,2020,17(27):24-28.
[12] 陈素玉.对终末期肾脏病患者血清Rock2的水平与其各项临床指标相关性的研究[J].当代医药论丛,2020,18(8):171-173.
[13] 高四红,任建立.氨氯地平并缬沙坦对高血压合并肾损伤患者自主神经功能及血清Rho相关蛋白激酶1的影响[J].心血管康复医学杂志,2019,28(1):87-91. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1257-1259. |
|
|
|
|
2022, Vol. 39 
